Targets › NISCH
1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout Dec 2028.
Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. (UniProt, Q9Y2I1)
Open in Phaseline: the race on NISCH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vanderbilt University Medical Center | Moxonidine Nischarin agonist | NISCH | Phase 1 | Obesity | Dec 2028 |
Obesity (1)
small molecule (1)
Vanderbilt University Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.